本帖最后由 老马 于 2012-1-13 21:20 编辑 9 E8 n! _% }9 N+ ]
) W6 |4 }1 ?$ R; x" M3 u爱必妥和阿瓦斯丁的比较1 u# L n- l: \ ?& v
; V( v ?1 d6 |9 g+ {1 Y1 N
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/$ O2 G, I: ^ i+ H" P
' B) Y6 F6 Y0 Z: r) k3 s4 J. d
3 v% u' M& |0 Y* m" _http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
& A' ]. v* a! K0 d==================================================$ p3 d7 ]8 R! L5 r9 x- @
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) J" {7 k9 i4 R( ^* m4 C
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ J( X) _# W5 J4 W/ N" }Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 B, k/ t1 L9 g% E0 K$ c% k
|
显身卡
/ X2 D A) A: w2 l0 ]7 ^7 T7 M
